Terns Pharmaceuticals Company Leadership
| TERN Stock | USD 3.35 0.21 6.69% |
About 73% of Terns Pharmaceuticals' corporate insiders are selling. The analysis of insiders' sentiment of trading Terns Pharmaceuticals stock suggests that many insiders are alarmed at this time. Terns Pharmaceuticals employs about 18 people. The company is managed by 18 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Insider Sentiment 27
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-01-06 | Mark J Vignola | Disposed 9059 @ 5.8 | View | ||
| 2025-01-02 | Mark J Vignola | Disposed 8129 @ 5.72 | View | ||
| 2024-12-05 | Amy L Burroughs | Acquired 15450 @ 7.15 | View | ||
| 2024-11-30 | Melita Sun Jung | Acquired 2250 @ 5.11 | View | ||
| 2024-09-12 | Hongbo Lu | Acquired 476190 @ 10.5 | View | ||
| 2024-09-10 | Mark J Vignola | Disposed 10000 @ 11 | View | ||
| 2024-09-09 | Jill M Quigley | Disposed 17235 @ 10 | View | ||
| 2024-08-01 | Jill M Quigley | Disposed 6143 @ 7.68 | View | ||
| 2024-07-15 | Carl L Gordon | Disposed 50976 @ 10 | View | ||
| 2024-04-03 | Vivo Opportunity, Llc | Disposed 138066 @ 6.2 | View | ||
| 2024-04-01 | Vivo Opportunity, Llc | Disposed 181117 @ 6.99 | View |
Monitoring Terns Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Terns |
Terns Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Terns Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Terns will maintain a workforce of about 30 employees by April 2025.Terns Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2013) % which means that it has lost $0.2013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2956) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.31. As of the 24th of March 2025, Net Tangible Assets is likely to grow to about 334.4 M, while Total Assets are likely to drop about 203.2 M.As of the 24th of March 2025, Common Stock Shares Outstanding is likely to drop to about 45 M. In addition to that, Net Loss is likely to drop to about (57 M)
Terns Pharmaceuticals Workforce Comparison
Terns Pharmaceuticals is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 725. Terns Pharmaceuticals adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Terns Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Terns Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 2.0 | 10 | 5 | 2,786,278 | 36,669 |
| 2024-09-01 | 0.5455 | 12 | 22 | 549,753 | 211,328 |
| 2024-06-01 | 1.1111 | 10 | 9 | 708,582 | 420,663 |
| 2024-03-01 | 3.0 | 9 | 3 | 2,052,500 | 397,500 |
| 2022-12-01 | 2.3333 | 7 | 3 | 1,793,111 | 1,500,000 |
| 2021-03-01 | 0.7778 | 21 | 27 | 17,471,140 | 11,035,324 |
| 2003-12-01 | 0.4286 | 3 | 7 | 16,341 | 32,741 |
Terns Pharmaceuticals Notable Stakeholders
A Terns Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Terns Pharmaceuticals often face trade-offs trying to please all of them. Terns Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Terns Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Amy MBA | CEO Director | Profile | |
| Erin MD | President Development | Profile | |
| Seokho Esq | General COO | Profile | |
| David Strauss | VP Controller | Profile | |
| Pamela Danagher | Senior Assurance | Profile | |
| Debra Sieminski | Senior Affairs | Profile | |
| Jeffrey Jasper | Senior Research | Profile | |
| JD Esq | Chief Officer | Profile | |
| Senthil Sundaram | CEO Director | Profile | |
| Kerry MD | Chief Officer | Profile | |
| Emil MD | Chief Oncology | Profile | |
| Andrew Gengos | Chief Officer | Profile | |
| Weidong Zhong | CoFounder Officer | Profile | |
| Mark Vignola | CFO Treasurer | Profile | |
| Scott Harris | Chief Officer | Profile | |
| Diana Chung | Senior Officer | Profile | |
| Melita Jung | Chief Officer | Profile | |
| James Kanter | Senior CMC | Profile |
About Terns Pharmaceuticals Management Performance
The success or failure of an entity such as Terns Pharmaceuticals often depends on how effective the management is. Terns Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Terns management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Terns management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.27) |
Terns Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Terns Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Terns Pharmaceuticals within its industry.Terns Pharmaceuticals Manpower Efficiency
Return on Terns Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.9M | |
| Net Loss Per Executive | 4.9M | |
| Working Capital Per Employee | 19.2M | |
| Working Capital Per Executive | 19.2M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.